Premium
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Author(s) -
Bagalkot Vaishali,
Farokhzad Omid C.,
Langer Robert,
Jon Sangyong
Publication year - 2006
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.200602251
Subject(s) - aptamer , conjugate , doxorubicin , drug delivery , chemistry , targeted drug delivery , drug , drug carrier , antibody drug conjugate , pharmacology , intracellular , cancer research , biophysics , microbiology and biotechnology , biochemistry , biology , chemotherapy , immunology , antibody , monoclonal antibody , mathematical analysis , mathematics , organic chemistry , genetics
Trojan aptamer : A novel strategy for targeted drug delivery to cancer cells was developed through the formation of a physical conjugate (see scheme) between doxorubicin (Dox) and the A10 RNA aptamer that binds to the prostate‐specific membrane antigen (PSMA). The aptamer–Dox conjugate could efficiently bind to PSMA‐expressing cells, thereby resulting in its uptake and the intracellular release of Dox.